Johnson & Johnson rare blood clot concerns deal new blow to global vaccination drive
CNN
Reports that the Johnson & Johnson Covid-19 vaccine may, in extremely rare cases, cause blood clots has dealt a fresh blow to the world's vaccination drive, just weeks after similar concerns were raised over the vaccine developed by AstraZeneca and Oxford University.
On Tuesday, Johnson & Johnson said it would suspend shots across the United States while federal health agencies investigated a small number of rare blood clot cases, a move that some experts fear will erode vaccine confidence. Outside of the US, Johnson & Johnson said it would delay the rollout of its vaccine in Europe, where several countries were due to begin administering shots this week. South Africa, which has been hit hard by a more contagious variant of the virus, has halted use of the Johnson & Johnson vaccine as a precautionary measure. Australia said it will not purchase any doses from the company, citing concerns over it being the same type as the AstraZeneca vaccine.More Related News